- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03949894
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)
June 15, 2022 updated by: Korea Otsuka Pharmaceutical Co., Ltd.
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at initiation of treatment.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
118
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Busan, Korea, Republic of
- Inje University Busan Paik Hospital
-
Busan, Korea, Republic of
- Kosin University Gospel Hospital
-
Chuncheon, Korea, Republic of
- Hallym University Chuncheon Sacred Heart Hospital
-
Daegu, Korea, Republic of
- Keimyung University Dongsan Medical Center
-
Daegu, Korea, Republic of
- Kyungpook National University Hospital
-
Daejeon, Korea, Republic of
- Chungnam National University Hospital
-
Gwangju, Korea, Republic of
- Chonnam National University Hospital
-
Incheon, Korea, Republic of
- Gachon University Gil Medical Center
-
Pyeongchon, Korea, Republic of
- Hallym University Medical Center
-
Seongnam-si, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of
- Severance Hospital
-
Seoul, Korea, Republic of
- SMG-SNU Boramae Medical Center
-
Seoul, Korea, Republic of
- Kangbuk Samsung Hospital
-
Seoul, Korea, Republic of
- Hanyang University Seoul Hospital
-
Seoul, Korea, Republic of
- Hallym University Kangnam Sacred Heart Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 50 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who voluntarily participate by giving written informed consent on this trial
- Male and female patients aged ≥ 19 to ≤ 50 years
- Subjects diagnosed with ADPKD based on the Unified Criteria for Ultrasonographic diagnosis of ADPKD (Pei-Ravine Criteria)
- Subjects with confirmed CKD stages 1-3 at the screening visit
Subjects with confirmed rapidly progressive typical ADPKD 'Typical ADPKD'
- refers to bilateral and diffuse distribution, with mild, moderate or severe replacement of kidney tissue by cysts, where all cysts contribute similarly to TKV.
'rapidly progressive ADPKD'
Patients will be defined as 'rapidly progressive ADPKD' if they meet any of the following criteria:
Mayo class 1C, 1D or 1E
- Truncating PKD1 mutation confirmed by genetic testing before participating this trial ③ PRO-PKD score > 6 ④ Patients with ADPKD with a decline in Estimated glomerular filtration rate(eGFR) ≥ 5 mL/min/1.73 m2 within 1 year from the screening visit or with an average annual decline in eGFR ≥ 2.5 mL/min/1.73 m2 over a period of 5 years (excluding patients with an eGFR decline due to factors other than ADPKD, such as uncontrolled type 2 diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis)
Exclusion Criteria:
- Patients with hyponatremia or hypernatremia
- Patients with anuria
- Patients with volume depletion
- Patients who are unable to sense or appropriately respond to thirst
- Patients with contraindications to MRI assessment [e.g., ferromagnetic metal prosthesis, aneurysm clips, severe claustrophobia, large tattoo on the abdomen or back, etc.]
- Patients with severe renal impairment [e.g., patients with currently active glomerulonephritis, kidney cancer, having a single kidney, history of renal surgery within the last 3 years, etc.]
- Patients with severe hepatic impairment [e.g., cirrhosis, viral hepatitis, unspecified liver function test abnormalities (ALT or Aspartate aminotransferase(AST)) > 3 x ULN or Total Bilirubin > 2 x ULN), etc.]
- Patients with eGFR decline due to factors other than ADPKD (e.g., uncontrolled type 2 diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis, etc.)
- Patients with a history of hypersensitivity and/or specific reactions to benzazepine or benzazepine derivatives (such as Benazepril), or tolvaptan
- Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients who need chronic diuretic use
- Patients who are receiving any experimental (not marketed) or approved therapies that may affect the treatment of ADPKD within 6 months from the screening visit [e.g., anti-sense RNA therapy, rapamycin, sirolimus, everolimus and somatostatin analogs (octreotide, sandostatin), vasopressin antagonist (mozavaptan, conivaptan), vasopressin agonist (desmopressin)]
- Patients who have received cyst decompression or sclerotherapy within 3 years from the screening visit
- Patients with a history of taking tolvaptan within 6 months from the screening visit
- Patients who received any investigational medicinal product in another trial within 30 days from the screening visit
- Fertile women who are currently pregnant or breat feeding, or not willing to use or capable of using acceptable contraceptive methods (abstinence, oral, implanted or injected hormonal methods of contraception, intrauterine device or barrier methods of contraception, such as condom, contraceptive diaphragm and spermicidal agents) to avoid pregnancy until completion of the trial
- Patients who are, in the opinion of the investigator, unable to comply with the administration of the Investigational Medicinal Product(IMP) or the trial procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: tolvaptan
|
30mg and 15mg of Tolvaptan Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidences of TEAEs
Time Frame: during the tolvaptan treatment period and up to 7 days after the date of last dosing
|
The incidences of TEAEs
|
during the tolvaptan treatment period and up to 7 days after the date of last dosing
|
The incidences of TEAEs meeting any of the followings will be summarized.
Time Frame: during the tolvaptan treatment period and up to 7 days after the date of last dosing
|
Liver injury [ALT or AST elevation (>3 x ULN) or Total Bilirubin elevation (>2 x ULN), etc.], AEs leading to death, Serious AEs, AEs leading to treatment discontinuation, AEs whose causal relationship with the IMP cannot be ruled out, Severe AEs, Dehydration, Effects on Sodium, Creatinine
|
during the tolvaptan treatment period and up to 7 days after the date of last dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total kidney volume (TKV) annual mean percent change rate [%/year]
Time Frame: from baseline to End of Treatment (Visit 25, Month 24)
|
Baseline TKV refers to the value measured during the screening period
|
from baseline to End of Treatment (Visit 25, Month 24)
|
eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (off-treatment)
Time Frame: from baseline to the Follow-up visit (Visit 26, 7 days after End of Treatment(Visit 25, Month 24))
|
(off-treatment)
|
from baseline to the Follow-up visit (Visit 26, 7 days after End of Treatment(Visit 25, Month 24))
|
eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (on-treatment)
Time Frame: from Completion of Tolvaptan Titration Period (Visit 6, Week 4) to End of Treatment (Visit 25, Month 24)
|
(on-treatment)
|
from Completion of Tolvaptan Titration Period (Visit 6, Week 4) to End of Treatment (Visit 25, Month 24)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2019
Primary Completion (ACTUAL)
May 25, 2022
Study Completion (ACTUAL)
May 25, 2022
Study Registration Dates
First Submitted
April 16, 2019
First Submitted That Met QC Criteria
May 13, 2019
First Posted (ACTUAL)
May 14, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 16, 2022
Last Update Submitted That Met QC Criteria
June 15, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Musculoskeletal Abnormalities
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Kidney Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Arthrogryposis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Antidiuretic Hormone Receptor Antagonists
- Tolvaptan
Other Study ID Numbers
- 156-402-00144
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of North Carolina, Chapel HillNational Institute of General Medical Sciences (NIGMS)CompletedRenal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKDUnited States
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Assistance Publique - Hôpitaux de ParisIPSEN pharmaceutical company, Boulogne-Billancourt, FranceCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKDFrance
-
University Medical Center GroningenRadboud University Medical Center; Erasmus Medical Center; Leiden University...UnknownAutosomal Dominant Polycystic Kidney Disease (ADPKD)Netherlands
-
Mario Negri Institute for Pharmacological ResearchCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Italy
-
Palladio BiosciencesCentessa Pharmaceuticals plcTerminatedADPKD | Polycystic Kidney Disease, AdultUnited States
-
Tufts Medical CenterCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Children's National Research InstituteRecruiting
-
University of CologneRecruitingADPKD (Autosomal Dominant Polycystic Kidney Disease)Germany
-
University of ZurichCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Switzerland
Clinical Trials on Tolvaptan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)United States, United Kingdom, Belgium, Poland, France, Germany, Italy
-
Regional Hospital HolstebroAarhus University HospitalCompleted
-
NYU Langone HealthWithdrawnSIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic OsmostatUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Eli Lilly and CompanyActive, not recruitingPlaque Psoriasis | Psoriatic ArthritisIndia
-
Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney, Autosomal DominantJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
University of North Carolina, Chapel HillOtsuka America PharmaceuticalCompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States